US · MDXG · BIOTECHNOLOGY
MiMedx Group, Inc. (MDXG) intrinsic value and stock valuation
$3.05as of 2026-11-21 · Mkt cap 606.36M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
MiMedx Group, Inc. DCF and intrinsic value
InvestorsCraft values MDXG with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MDXG’s statements →
MiMedx Group, Inc. Graham Number
Graham Number: $3.58d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Dianthus Therapeutics, Inc. (DNTH) $84.55
- Atai Beckley Inc. (ATAI) $7.35
- Nektar Therapeutics (NKTR) $30.20
- Taysha Gene Therapies, Inc. (TSHA) $3.72
- Rapport Therapeutics, Inc. Common Stock (RAPP) $23.16
- Syndax Pharmaceuticals, Inc. (SNDX) $8.72
- Innoviva, Inc. (INVA) $18.41
- Inhibrx Biosciences Inc. (INBX) $68.97
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $418.6M | $348.9M | $321.5M | $267.8M | $242M |
| Operating income | $63.9M | $58.9M | $37.1M | -$-14.73M | -$-7.05M |
| Net income | $48.6M | $42.4M | $67.4M | -$-30.2M | -$-12.3M |
| EPSd | $324.5K | $284.6K | $462K | -$-267.47K | -$-111.46K |
| Operating cash flow | $74M | $66.2M | $26.8M | -$-17.89M | -$-1.98M |
| Capital expenditure | -$-1.03M | -$-1.68M | -$-1.99M | -$-1.51M | -$-3.22M |
| Free cash flow | $73M | $64.5M | $24.8M | -$-19.41M | -$-5.2M |
| Total assets | $342.7M | $263.9M | $239.1M | $171.4M | $187.9M |
| Total debt | $22.5M | $24.8M | $48.1M | $52.5M | $53.3M |
| Net debt | -$-143.59M | -$-79.57M | -$-33.9M | -$-13.48M | -$-33.79M |
| Total equity | $256.6M | $193.1M | $142.7M | $74.5M | $92.6M |
| Cash and short-term investments | $166.1M | $104.4M | $82M | $66M | $87.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $418.6M | $348.9M | $321.5M | $267.8M | $242M |
| Cost of revenue | $73M | $60.1M | $54.6M | $48.3M | $39.6M |
| Gross profit | $345.6M | $288.8M | $266.8M | $219.5M | $202.4M |
| Research and development expenses | $15.1M | $12.3M | $12.7M | $12.7M | $9.93M |
| Selling, general and administrative expenses | $266.2M | $216.4M | $216.3M | $220.9M | $194.9M |
| Other expenses | $0.00 | $1.21M | $760K | $700K | $4.66M |
| Operating expenses | $281.3M | $229.9M | $229.7M | $234.3M | $209.4M |
| Cost and expenses | $354.7M | $290M | $284.4M | $282.6M | $249.1M |
| Interest income | $4.72M | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $1.78M | $1.01M | $6.46M | $5.02M | $4.98M |
| Depreciation and amortization | $14.9M | $6.04M | $3.43M | $4.05M | $5.18M |
| Ebitda | $82.9M | $65.4M | $40.5M | -$-10.69M | -$-1.89M |
| Operating income | $63.9M | $58.9M | $37.1M | -$-14.73M | -$-7.05M |
| Total other income/expenses, net | $2.38M | -$-1.57M | -$-6.48M | -$-5.02M | -$-5M |
| Income before tax | $66.3M | $57.3M | $30.6M | -$-19.75M | -$-12.05M |
| Income tax expense | $17.7M | $15.3M | -$-36.81M | $210K | $250K |
| Net income | $48.6M | $42.4M | $67.4M | -$-30.2M | -$-12.3M |
| Weighted average shares outstanding | $147.8M | $147M | $116.5M | $112.9M | $110.4M |
| Weighted average diluted shares outstanding | $149.7M | $149.1M | $146M | $112.9M | $110.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $166.1M | $104.4M | $82M | $66M | $87.1M |
| Net receivables | $75.7M | $55.8M | $53.9M | $43.1M | $40.4M |
| Inventory | $25.3M | $23.8M | $21M | $13.2M | $11.4M |
| Total current assets | $277.5M | $191.9M | $164.3M | $134.2M | $148.5M |
| Property, plant and equipment, net | $4.71M | $11.6M | $9.11M | $11.3M | $13.9M |
| Goodwill and intangible assets | $33.6M | $31.1M | $24.7M | $25.3M | $25.4M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $65.2M | $72M | $74.8M | $37.2M | $39.4M |
| Total assets | $342.7M | $263.9M | $239.1M | $171.4M | $187.9M |
| Accounts payable | $14.5M | $7.41M | $9.05M | $8.45M | $7.38M |
| Short-term debt | $2.82M | $2.31M | $0.00 | $1.44M | $1.25M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $64.3M | $45.6M | $46M | $43.6M | $42.4M |
| Long-term debt | $19.7M | $22.5M | $48.1M | $51M | $52.1M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $21.8M | $25.2M | $50.3M | $53.4M | $53M |
| Capital lease obligations | $3.25M | $6.01M | $0.00 | $2.44M | $5.17M |
| Total liabilities | $86.1M | $70.8M | $96.3M | $96.9M | $95.4M |
| Common stock | $150K | $150K | $150K | $110K | $110K |
| Retained earnings | -$-42.68M | -$-91.26M | -$-133.68M | -$-191.91M | -$-161.71M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $256.6M | $193.1M | $142.7M | $74.5M | $92.6M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $22.5M | $24.8M | $48.1M | $52.5M | $53.3M |
| Net debt | -$-143.59M | -$-79.57M | -$-33.9M | -$-13.48M | -$-33.79M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $48.6M | $42M | $67.4M | -$-19.95M | -$-12.3M |
| Depreciation and amortization | $14.9M | $6.04M | $3.43M | $4.05M | $5.18M |
| Stock-based compensation | $16.4M | $16.9M | $17M | $11.3M | $14.2M |
| Change in working capital | -$-22.98M | -$-5.43M | -$-18.42M | -$-8.01M | -$-19.35M |
| Accounts receivable | -$-26.39M | -$-2.55M | -$-12.24M | -$-5.94M | -$-10.62M |
| Inventory | -$-1.53M | -$-2.36M | -$-7.84M | -$-1.79M | -$-1.41M |
| Accounts payable | $2.12M | -$-1.41M | $780K | $840K | -$-160K |
| Net cash provided by operating activities | $74M | $66.2M | $26.8M | -$-17.89M | -$-1.98M |
| Investments in property, plant and equipment | -$-1.03M | -$-1.68M | -$-1.99M | -$-1.51M | -$-3.22M |
| Acquisitions, net | -$-3.76M | -$-7.86M | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-6.89M | -$-9.58M | -$-2.15M | -$-2.66M | -$-3.4M |
| Common stock issued | $0.00 | $1.4M | $1M | $650K | $1.44M |
| Common stock repurchased | -$-3.12M | -$-2.64M | -$-9.52M | -$-1.19M | -$-4.75M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-5.41M | -$-34.2M | -$-8.57M | -$-580K | -$-3.35M |
| Net change in cash | $61.7M | $22.4M | $16.1M | -$-21.13M | -$-8.73M |
| Cash at end of period | $166.1M | $104.4M | $82M | $66M | $87.1M |
| Operating cash flow | $74M | $66.2M | $26.8M | -$-17.89M | -$-1.98M |
| Capital expenditure | -$-1.03M | -$-1.68M | -$-1.99M | -$-1.51M | -$-3.22M |
| Free cash flow | $73M | $64.5M | $24.8M | -$-19.41M | -$-5.2M |
Line items
Line items
Line items
About MiMedx Group, Inc.
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.
- CEO
- Joseph H. Capper
- Employees
- 808
- Beta
- 1.45
Explore
Frequently asked questions
What is the intrinsic value of MiMedx Group, Inc. (MDXG)?
MiMedx Group, Inc. (MDXG) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is MDXG undervalued?
MDXG trades at a price of $3.05 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.